irasia.com


Living Cell Technologies Limited

Board and Management Team

The Board of Directors

Mr Roy Austin BCom, CA (Chairman - Appointed on 20 July 2011) (Independent Director)
Emeritus Professor Robert Elliott MBBS, MD, FRACP
Dr Bernie Tuch BSc, MBBS (Hons), FRACP and Ph D (Independent Director) (Appointed on 20 July 2011)
Mr Robert Willcocks BA, LLM (Independent Director) (Appointed on 29 March 2011)
Mr Laurie Hunter MA (Hons) (Independent Director)
Mr Nicholas Geddes (Company Secretary)

Dr Andrea Grant PhD, BA (Hons) (Managing Director) (Resigned on 1 April 2014)

Management Team

Dr Ken Taylor (Chief Executive) (Appointed on 8 July 2014)
Emeritus Professor Robert Elliott MBBS, MD, FRACP (Director, Clinical Research and Innovation)
Mr John Cowan (Head of Finance and Administration)

Dr Andrea Grant PhD, BA (Hons) (Managing Director) (Stepped down upon appointment as Diatranz Otsuka Limited's CEO on 1 April 2014)
Dr Paul Tan MB, BS, FRACP (Chief Science and Medical Officer) (Retired on 21 January 2014)

Scientific Advisors

Professor Anne Young MD, PhD (Scientific Advisor) (Appointed on 23 September 2014 )
Professor Roger Barker MD, PhD, FRCP (Scientific Advisor) (Appointed on 23 September 2014)
Professor Richard Faull ONZM, MBChB, PhD, DSc, FRSNZ, (Scientific Advisor) (Appointed on 23 September 2014)



The Board of Directors

Mr Roy Austin BCom, CA, Chairman (Appointed on 20 July 2011), Independent Director

Mr Austin is a consultant to investment banking firm Northington Partners in New Zealand. He brings considerable commercial depth to the LCT Board with over 25 years' investment transaction experience across multiple sectors including healthcare and biotechnology. His experience includes capital raisings, mergers and acquisitions, IP commercialisation, venture capital and international business development.

Mr Austin is Chairman of New Zealand based Cure Kids, a child health research charitable trust and its commercial biotech venture capital fund, Cure Kids Ventures Limited.

He holds a number of other directorships in private companies has a BCom and is a member of the New Zealand Institute of Directors and the New Zealand Institute of Chartered Accountants.

Mr Austin became the Acting Chairman of the Board following Dr Macdonald's resignation on 24 June 2011. He was elected Chairman on 20 July 2011.

He is the Chair of the Remuneration & Nomination committee and a member of the Audit Risk & Compliance committee.

He was appointed to the board on 25 February 2011.

back to top

Emeritus Professor Robert Elliott MBBS, MD, FRACP, Director, Clinical Research and Innovation

Professor Elliott trained as a Paediatrician at Adelaide University. He moved to New Zealand in 1970 to become the Foundation Professor, Director of Paediatrics at The University of Auckland. Professor Elliott co founded LCT. He is an Emeritus Professor of Child Health Research and a world leader in diabetes and autoimmune related research.

In 1999 he was awarded a CNZM (a Companion of the New Zealand Order of Merit) for services to the community. In 2011 he was awarded the prestigious World Class New Zealander (Life Sciences) award.

He is on the board of Cure Kids, Wings Trust (a NZ trust for the treatment of alcohol and substance abuse) and patron of the NZ Cystic Fibrosis Foundation. He is a director of Breath Easy Limited, a New Zealand company that is developing a new treatment for cystic fibrosis.

He was appointed to the board on 15 January 2004.

back to top

Dr Bernie Tuch BSc, MBBS (Hons), FRACP and Ph D, Independent Director (Appointed on 20 July 2011)

Dr Tuch is currently employed as a senior scientist with CSIRO Australia in a cell transplantation project. He was previously a Professor at the University of New South Wales, where he carried out extensive research in islet xenotransplantation over many decades. He is a director of Sydney Cell Therapy Foundation Pty Limited and is a Specialist Practitioner, Endocrinology, Prince of Wales Private Hospital, Sydney and is affiliated with universities in India and USA.

His experience includes capital raising to support his considerable research team and a large international scientific publication list. He has had previous scientific collaborations with LCT and knows the company's direction intimately.

Dr Tuch is a member of the Remuneration & Nomination committee.

He was appointed to the board on 20 July 2011.

back to top

Mr Robert Willcocks BA, LLM, Independent Director (Appointed on 29 March 2011)

Robert Willcocks is a senior executive with an extensive legal and business background working in particular with Australian listed public companies. He has Bachelor of Arts and Bachelor of Laws degrees from the Australian National University and a Master of Laws degree from the University of Sydney. Mr Willcocks was a partner with the law firm Stephen Jaques & Stephen (now Mallesons Stephen Jaques) from 1980 until 1994, where he was a member of the Corporate Advisory Group with an emphasis on the mining and oil and gas sectors. As corporate adviser he has undertaken assignments in a range of industry sectors.

Mr Willcocks has been a director and Chairman of a number of Australian Securities Exchange (ASX) listed public companies. He is a director of ASX listed ARC Exploration Limited, and Hong Kong Stock Exchange listed APAC Resources Ltd. He is also chairman and director of Trilogy Funds Management Ltd, a Responsible Entity under Australian law.

Mr Willcocks is chairman of the Audit Risk & Compliance committee and a member of the Remuneration & Nomination committee.

He was appointed to the board on 29 March 2011.

back to top

Mr Laurie Hunter MA (Hons), Independent Director

Mr Hunter has over 40 years' experience as a stockbroker, investment banker and corporate investor in London, Paris and San Francisco. Laurie was a Member of The Stock Exchange, London, a partner at L. Messel and Co, London, a director of Shearson Lehman Hutton and founder of Hunter Capital. His recent focus has been on investing and providing strategic advice to developing companies.

Mr Hunter currently serves on a number of boards including Madagascar Oil Limited where he is chairman and CEO.

Mr Hunter is a member of the Audit Risk & Compliance and Remuneration & Nomination committees.

He was appointed to the board on 25 August 2006.

back to top

Mr Nicholas Geddes, Company Secretary

Nick is the principal of Australian Company Secretaries, a company secretarial practice that he formed in 1993. Nick is past President and past Board Chairman of Chartered Secretaries Australia and a former Chairman of the NSW Council of that Institute. His previous experience, as a Chartered Accountant and Company Secretary, includes investment banking and development and venture capital in Europe, Africa the Middle East and Asia. Qualifications: Chartered Accountant (Fellow of Institute of Chartered Accountants in England and Wales) and Fellow of the Institute of Chartered Secretaries (Chartered Secretaries Australia).

back to top

Management Team

Dr Ken Taylor, Chief Executive (Appointed on 8 July 2014)

Dr Taylor joins LCT following a prestigious international career in both academia and business. He completed a postdoctoral fellowship in Pharmacology and Experimental Therapeutics at the Johns Hopkins University School of Medicine in Maryland, USA, and subsequently held a joint appointment in neurosciences at Princeton University and the Squibb Institute of Medical Research in Princeton, New Jersey.

He joined Roche Australia and was soon promoted to the role of Medical Director, Australia; before becoming Managing Director of Roche New Zealand.

In 1990, he was appointed Managing Director of the Roche UK affiliate and then transferred to Syntex in Palo Alto, California to convert the corporate pharmaceutical company to the Roche Bioscience Research Center.

Prior to joining LCT, Dr Taylor was CEO of Antipodean Pharmaceuticals where he managed the Phase I and II studies of its lead compound in Parkinson's disease.

New Zealand-born Dr Taylor holds Honours and Doctorate degrees in pharmaceutical chemistry and pharmacology from the University of Otago School of Medicine and completed a business management program at IMD in Lausanne, Switzerland.

back to top

Mr John Cowan, Head of Finance and Administration

Mr Cowan has over 30 years experience in senior finance positions in publicly listed companies with international operations and public benefit entities. He was Head Finance & Facilities at Auckland War Memorial Museum, CFO at the University of Auckland, Company Secretary at Mair Astley Limited and held senior finance positions in the Goodman Fielder Wattie Group.

He holds a BCA from Victoria University of Wellington and is a Fellow of the New Zealand Institute of Chartered Accountants.

back to top

Scientific Advisor
Three high-level scientific advisors appointed on 23 September 2014 to review and support LCT's work as NTCELL progresses towards commercialisation. All are internationally recognised experts on the discovery of new treatments for neurodegenerative diseases.

Professor Anne Young MD, PhD, Scientific Advisor (Appointed on 23 September 2014)

Prof Young is Distinguished Julieanne Dorn Professor of Neurology, Harvard Medical School, Boston, United States, she has over 40 years' experience studying functional neuroanatomy. Her current research focuses on studies of new therapeutic strategies for Parkinson's and Huntington's diseases.

back to top

Professor Roger Barker MD, PhD, FRCP, Scientific Advisor (Appointed on 23 September 2014)

Prof Barker is professor of Clinical Neurosciences and Deputy Director, John van Geest Centre for Brain Repair, University of Cambridge, United Kingdom, has extensive experience in evaluating and developing new therapies for Parkinson's and Huntington's diseases including cell therapies. His studies focus on disease heterogeneity using cognitive testing, functional imaging and genetic biomarkers.

back to top

Professor Richard Faull ONZM, MBChB, PhD, DSc, FRSNZ, Scientific Advisor (Appointed on 23 September 2014)

Prof Faull is Distinguished Professor of Anatomy and Director, Centre for Brain Research, University of Auckland School of Medicine, has over 40 years' research experience in anatomical studies of human brain neuronal growth. He directs the Centre for Brain Research which carries out research and development programs targeting neurodegenerative diseases such as Parkinson's, Huntington's, motor neuron and Alzheimer's diseases. "

back to top

updated 23rd September, 2014


  • Company's Index
  • irasia.com

  • © Copyright 1996-2014 irasia.com Ltd. All rights reserved.
    DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd be liable for damages resulting from the use of the information provided on this website.
    TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited.
    TERMS OF USE: Please read the Terms of Use governing the use of our website.